Cyclooxygenase, often shortened to COX, is an enzyme that converts a fatty acid in your cell membranes into prostaglandins, the chemical messengers that trigger pain, inflammation, and fever. It’s also the enzyme that every common pain reliever targets. When you take ibuprofen or aspirin, you’re blocking cyclooxygenase from doing its job. Understanding this enzyme explains why those drugs work, why they cause side effects like stomach irritation, and why your body needs prostaglandins in the first place.
What COX Does in Your Body
Cyclooxygenase acts on arachidonic acid, a fatty acid released from cell membranes when tissue is damaged or inflamed. COX is the rate-limiting step in prostaglandin production, meaning it controls how fast and how much prostaglandin your body makes. The enzyme converts arachidonic acid first into an intermediate molecule called PGG2, then into PGH2. From there, other enzymes shape PGH2 into specific prostaglandins and related compounds, each with a different role.
The end products do a wide range of things. Some prostaglandins sensitize nerve endings to pain. Others dilate blood vessels, producing the redness and swelling of inflammation. One particular prostaglandin, PGE2, is the key driver of fever. It acts on a thermoregulation center in the hypothalamus, the part of your brain that functions like an internal thermostat. When your immune system detects an infection, it releases signaling molecules that ramp up COX activity in the brain, producing PGE2 and effectively raising your body’s temperature set point. That’s why blocking COX with a pain reliever also brings down a fever.
Another important COX product is thromboxane A2, which helps platelets clump together to form blood clots. This is essential for stopping bleeding from a wound, but excessive clotting can cause heart attacks and strokes.
Two Forms: COX-1 and COX-2
Your body produces two main versions of cyclooxygenase, and they serve fundamentally different purposes.
COX-1 is always active. It’s present in nearly every tissue, including the stomach lining, kidneys, blood vessels, and platelets. Think of it as a housekeeping enzyme. In the stomach, COX-1 produces prostaglandins that stimulate the mucus layer protecting your stomach wall from its own acid. In the kidneys, it helps regulate blood flow. In platelets, it’s the only form of COX present, and it generates the thromboxane A2 that enables normal blood clotting.
COX-2 is different. Most tissues don’t produce it under normal conditions. Instead, it gets switched on by inflammation, injury, or infection. When immune cells like macrophages encounter bacteria, they rapidly produce COX-2, which churns out prostaglandins that cause pain, swelling, and fever. This makes COX-2 the primary target when you want to reduce inflammation without disrupting the body’s routine functions. There are a few exceptions to the “only during inflammation” rule: the brain, kidneys, and uterus maintain low levels of COX-2 all the time. In the brain, COX-2 contributes to memory consolidation and normal nerve signaling. It also plays a role in bone healing, as studies have found that removing COX-2 activity impairs fracture repair while removing COX-1 does not.
How Pain Relievers Block COX
Nonsteroidal anti-inflammatory drugs, or NSAIDs, work by physically occupying the channel-shaped active site where arachidonic acid normally binds to the COX enzyme. They compete with arachidonic acid for that space, preventing the enzyme from producing prostaglandins. Fewer prostaglandins means less pain, less inflammation, and lower fever.
Traditional NSAIDs like ibuprofen and naproxen block both COX-1 and COX-2. This is why they’re effective against pain and inflammation but can irritate the stomach. By shutting down COX-1 in the stomach lining, they reduce the protective mucus layer, leaving it more vulnerable to acid damage. Long-term use raises the risk of ulcers and gastrointestinal bleeding.
Aspirin is a special case. Unlike other NSAIDs, which bind reversibly, aspirin permanently disables COX by attaching a chemical group (an acetyl group) to a specific spot inside the enzyme’s active site. The enzyme can never function again. This distinction matters most for platelets, which lack a nucleus and cannot produce new proteins. Once aspirin disables COX-1 in a platelet, that platelet can no longer generate thromboxane A2 for the rest of its life span, roughly 8 to 10 days. Since about 10 to 12% of your platelets are replaced each day, the anti-clotting effect gradually fades. This irreversible mechanism is why low-dose aspirin is used to reduce the risk of heart attacks and strokes.
Selective COX-2 Inhibitors
Because blocking COX-1 causes stomach problems, researchers developed drugs designed to target only COX-2. This was possible because the two enzymes have slightly different shapes. COX-2 has a larger active site channel, about 20% bigger than COX-1, with an additional side pocket that COX-1 lacks. Selective COX-2 inhibitors are shaped to fit into this extra pocket, allowing them to block COX-2 while largely leaving COX-1 alone.
The first wave of these drugs, called coxibs, included rofecoxib (Vioxx) and valdecoxib (Bextra). They were initially celebrated for reducing pain without the stomach side effects of traditional NSAIDs. But both were pulled from the market, Vioxx in 2004 and Bextra in 2005, after evidence showed they increased the risk of heart attacks and strokes. The mechanism behind this risk involves a balance between two COX products. COX-2 in blood vessel walls produces prostacyclin, a molecule that relaxes vessels and discourages clotting. COX-1 in platelets produces thromboxane, which promotes clotting. Selective COX-2 inhibitors suppress prostacyclin while leaving thromboxane untouched, tipping the balance toward clot formation, higher blood pressure, and accelerated artery disease.
Celecoxib (Celebrex) remains the only selective COX-2 inhibitor still on the U.S. market. It carries a boxed warning about cardiovascular risk, as does every prescription NSAID.
The COX-3 Question
A third variant, COX-3, was identified in dog brain tissue and initially generated excitement because it appeared to explain how acetaminophen (Tylenol) works. Acetaminophen reduces pain and fever but has little anti-inflammatory effect, which doesn’t fit neatly into the COX-1/COX-2 framework. The idea was that COX-3 might be a brain-specific enzyme that acetaminophen selectively blocks.
That hypothesis has largely been set aside. While COX-3 messenger RNA has been detected in human tissues, the protein it would produce has not been shown to be functional or clinically relevant in humans. The mechanism behind acetaminophen’s pain-relieving effects remains incompletely understood, and COX-3 does not appear to be the answer.
Why COX Matters Beyond Pain
Cyclooxygenase is involved in far more than the experience of pain. Its products regulate blood flow in the kidneys, help maintain the stomach’s protective barrier, control how readily your blood clots, influence brain function, and drive the repair of broken bones. This wide reach is exactly why drugs that block COX have such a broad range of both benefits and side effects. Reducing prostaglandin production in one tissue relieves symptoms, while reducing it in another can cause harm. The entire history of NSAID development, from aspirin in the 1890s to the rise and fall of selective COX-2 inhibitors, has been shaped by attempts to target this single enzyme more precisely.